MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31.

Income Overview

Net Income
-$38,182K
EPS
-$0.72
Unit: Thousand (K) dollars

Income Statement
2025-12-31
Research and development
30,496
General and administrative
17,770
Total operating expenses
48,266
Loss from operations
-48,266
Grant income
89
Interest income
3,915
Interest expense
2,119
Change in fair value of warrant liabilities
-8,199
Total other income (expense), net
10,084
Net loss and comprehensive loss
-38,182
Basic EPS
-0.72
Diluted EPS
-0.72
Basic Average Shares
52,958,644
Diluted Average Shares
52,958,644
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Change in fair value ofwarrant liabilities-$8,199K Interest income$3,915K Grant income$89K Net loss andcomprehensive loss-$38,182K Total other income(expense), net$10,084K Interest expense$2,119K Loss from operations-$48,266K Total operatingexpenses$48,266K Research and development$30,496K General andadministrative$17,770K

Candel Therapeutics, Inc. (CADL)

Candel Therapeutics, Inc. (CADL)